Compare C.H. Robinson Worldwide, Inc. (CHRW) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C.H. Robinson Worldwide, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? C.H. Robinson Worldwide, Inc. trades at $147.55 (market cap $16.96B), while Regeneron Pharmaceuticals Inc trades at $795.3 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.8× C.H. Robinson Worldwide, Inc.'s market cap, and C.H. Robinson Worldwide, Inc. pays the higher dividend (1.74%). Which is the better fit depends on your goals.
| CHRW | REGN | |
|---|---|---|
Market Cap | $16.96B | $82.06B |
Sector | Industrials | Health |
52-Week High | $209.42 | $812.27 |
52-Week Low | $118.77 | $555.51 |
Enterprise Value | $18.78B | $76.77B |
Dividend Yield | 1.74% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CHRW trades at $148.29, down 0.71% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company has beaten EPS estimates for the last three quarters, with Q3 2026 expected at $1.65. Revenue for 2025 was $16.23B, with net income of $587.08M and a profit margin of 3.61%. Recent news includes the declaration of a quarterly dividend and participation in industry summits.
The outlook is mixed: strong profitability metrics like a 37.12% ROE and analyst consensus price target of $193.00 suggest upside, but bearish technicals and a high P/E of 27.7 indicate valuation concerns. Risks include freight demand volatility and legal challenges, as seen with the Dallas verdict appeal. Institutional buying activity provides support, but investors should weigh growth against current market sentiment.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
